>
IL-6 und IL-6-Rezeptorproteine
Menschen- und Mäusespezies sind verfügbar
Hohe Reinheit: >95%
Hohe Bioaktivität, nachgewiesen durch ELISA, BLI und zellbasierte Tests.Kostenlose Verfahrensvorschriften verfügbar
Verschiedene Tags: Tag Frei, His Tag, Avi & His Tag, Fc Tag
Geringes Endotoxin: < 1,0 EU/µg
Molekül | Kat. Nr. | Arten | Produktbeschreibung | Vorbestellung/Bestellung |
---|---|---|---|---|
IL-6 | IL6-H8218 | Human | Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity (primary amine labeling) |
|
IL-6 | IL6-H4218 | Human | ActiveMax® Human IL-6 Protein, Tag Free |
|
IL-6 | IL6-M5245 | Mouse | Mouse IL-6 Protein, His Tag |
|
IL-6 | IL6-M82Q7 | Mouse | Biotinylated Mouse IL-6 Protein, Avitag™,His Tag |
|
IL-6 | IL6-C5249 | Cynomolgus | Cynomolgus IL-6 Protein, His Tag (MALS verified) |
|
IL-6 R alpha | ILR-H4223 | Human | Human IL-6 R alpha / CD126 Protein, His Tag |
|
IL-6 R alpha | CD6-H82E8 | Human | Biotinylated Human IL-6 R alpha / CD126 Protein, Avitag™,His Tag |
|
IL-6 R alpha | ILR-H5259 | Human | Human IL-6 R alpha / CD126 Protein, Fc Tag |
|
IL-6 R alpha | ILR-M82E9 | Mouse | Biotinylated Mouse IL-6 R alpha / CD126 Protein, His,Avitag™ |
|
gp130 | ILT-M52H1 | Mouse | Mouse gp130 / CD130 / IL-6 R beta Protein, His Tag |
|
gp130 | ILT-M5252 | Mouse | Mouse gp130 / CD130 / IL-6 R beta Protein, Fc Tag |
|
Biotinylated Human IL-6 R alpha, Avitag, His Tag (Cat. No. CD6-H82E8) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%. The protein has a calculated MW of 41.7 kDa and migrates as 55-70 kDa due to glycosylation.
ActiveMax® Human IL-6, Tag Free (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2856-0.3636 ng/mL.
Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL.
>>【Inspiring Target】Therapeutic potential of IL-6 immunization in multiple fields continues to burst
Authors:Choy, E.H., De Benedetti, F., Takeuchi, T. et al.
Authors:Atal, S., Fatima, Z.
Authors:Anjali Dhall et al.
Authors: The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.
Authors:Fu, B., Xu, X. & Wei, H.
This web search service is supported by Google Inc.